Multiple Myeloma (MM) is a malignant plasma cell disorder with an unmet medical need, in
particular for relapsed and refractory patients. Molecules within deregulated signaling …

RAF, a core signaling component of the MAPK kinase cascade, is often mutated in various
cancers, including melanoma, lung, and colorectal cancers. The approved inhibitors were …

Abstract Abstract 942 The PI3K/Akt pathway mediates multiple myeloma (MM) cell growth
and drug resistance, and targeting this molecule is a promising therapeutic option. In this …

Introduction: Overall survival for patients with multiple myeloma (MM) has improved, but
most patients relapse and eventually succumb to complications of the disease. The …

Selective RAF inhibitors have significant activity in patients with metastatic melanoma whose
tumors express BRAFV600E. However, not all patients respond equally well to treatment …

Although rat sarcoma viral oncogene homolog (RAS) mutations occur in about 30% of solid
tumors, targeting RAS mutations other than KRAS-G12C is still challenging. As an …

Introduction Multiple myeloma (MM), relapsed or refractory (R/R) to standard of care
therapies, represents a treatment indication with a significant unmet clinical need …

Mutations in ERK signaling drive a significant percentage of malignancies. LY3009120, a
pan-RAF and dimer inhibitor, has preclinical activity in RAS-and BRAF-mutated cell lines …

SB743921 is a potent inhibitor of the spindle protein kinesin and is being investigated in
ongoing clinical trials for the treatment of myeloma. However, little is known about the …

RAS mutant tumors have proven largely refractory to inhibitors of the MAPK pathway in
clinic. In contrast, selective inhibitors of BRAFV600E but not wild type RAF have been …